Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys-Reference-Cited by-同舟云学术

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Published:2018-10-03 Issue:7731 Volume:563 Page:360-364
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Borducchi Erica N.,Liu Jinyan,Nkolola Joseph P.,Cadena Anthony M.,Yu Wen-Han,Fischinger Stephanie,Broge Thomas,Abbink Peter,Mercado Noe B.,Chandrashekar Abishek,Jetton David,Peter Lauren,McMahan Katherine,Moseley Edward T.,Bekerman Elena,Hesselgesser Joseph,Li Wenjun,Lewis Mark G.,Alter Galit,Geleziunas Romas,Barouch Dan H.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-018-0600-6.pdf

Reference27 articles.

1. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).

2. Persaud, D., Zhou, Y., Siliciano, J. M. & Siliciano, R. F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77, 1659–1665 (2003).

3. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193–13197 (1997).

4. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).

5. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).

Cited by 258 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study;Signal Transduction and Targeted Therapy;2024-09-09

2. Immune checkpoint inhibitors in infectious disease;Immunological Reviews;2024-09-09

3. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing;Communications Biology;2024-08-09

4. Modelling HIV-1 control and remission;npj Systems Biology and Applications;2024-08-08

5. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?;Viruses;2024-07-19